Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- Henlix, Inc
- Target Recruit Count
- 98
- Registration Number
- NCT04169178
- Locations
- 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
🇨🇳Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare, Taipei county, Taiwan
🇨🇳Tri-Service General Hospital, Taipei, Taiwan
Evaluate the Efficacy and Safety of HLX10 in Chronic Hepatitis B Patients
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: Recombinant anti-programmed death-1 (PD-1) humanized monoclonal antibodyDrug: Nucleoside/nucleotide analogues
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- Henlix, Inc
- Target Recruit Count
- 44
- Registration Number
- NCT04133259
- Locations
- 🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
🇨🇳China Medical University Hospital, Taichung, Taiwan
🇨🇳National Taiwan University Hospita, Taipei, Taiwan
A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors
- Conditions
- Solid Tumor, Adult
- Interventions
- Drug: HLX06
- First Posted Date
- 2018-04-11
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Henlix, Inc
- Target Recruit Count
- 5
- Registration Number
- NCT03494231
- Locations
- 🇨🇳
Taipei Medical University-Shuang Ho Hospital, New Taipei City, Taiwan
Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors
- First Posted Date
- 2018-03-19
- Last Posted Date
- 2020-06-01
- Lead Sponsor
- Henlix, Inc
- Target Recruit Count
- 30
- Registration Number
- NCT03468751
- Locations
- 🇨🇳
Taipei Municipal Wanfang Hospital, Taipei City, Taiwan
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers
- Conditions
- Solid Tumour
- Interventions
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Henlix, Inc
- Target Recruit Count
- 19
- Registration Number
- NCT02648490
- Locations
- 🇺🇸
Henlix, Inc., Fremont, California, United States
🇨🇳Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan